The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients

Published:2017-11-11 Issue:4 Volume:33 Page:367-373
ISSN:0910-8327
Container-title:Heart and Vessels
language:en
Short-container-title:Heart Vessels

Author:

Kiuchi Shunsuke,Hisatake Shinji,Kabuki Takayuki,Oka Takashi,Dobashi Shintaro,Fujii Takahiro,Ikeda Takanori

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/article/10.1007/s00380-017-1067-3/fulltext.html

Reference25 articles.

1. Matsuzaki M, Hori M, Izumi T, Fukunami M (2011) Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25(Suppl 1):S33–S45

2. Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Mitsuda T, Miura A, Imai R, Iwamiya S, Ozaki Y, Kato T, Miura T, Watarai M, Murohara T (2016) Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Heart Vessels 31:1643–1649

3. Imamura T, Kinugawa K (2016) Tolvaptan improves the long-term prognosis in patients with congestive heart failure with preserved ejection fraction as well as in those with reduced ejection fraction. Int Heart J 57:600–606

4. Hanatani A, Shibata A, Kitada R, Iwata S, Matsumura Y, Doi A, Sugioka K, Takagi M, Yoshiyama M (2017) Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Heart Vessels 32:287–294

5. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. the EVEREST outcome trial. JAMA 297:1319–1331

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of urea administration for the treatment of hyponatremia in heart failure;Medicina Clínica (English Edition);2024-01

2. Efectividad de la administración de urea para el tratamiento de la hiponatremia en la insuficiencia cardiaca;Medicina Clínica;2024-01

3. Early Initiation of Dapagliflozin during Hospitalization for Acute Heart Failure Is Associated with a Shorter Hospital Stay;Internal Medicine;2023-11-01

4. Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients;Pharmacology Research & Perspectives;2023-04-27

5. Innovative clinical pathway shortened the length of hospital stay and prevented readmission in patients with acute decompensated heart failure;Journal of Cardiology;2022-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3